Santhera gibt die Zulassung von AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie in Hongkong bekannt
20 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
Die Gesundheitsbehörde (Department of Health, DoH) von Hongkong hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 4 Jahren zugelassen Vor kurzem hat China’s National...
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
20 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National...
Santhera gibt die Zulassung von AGAMREE® (Vamorolone) zur Behandlung von Duchenne-Muskeldystrophie durch Chinas NMPA bekannt
11 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
Chinas National Medical Products Administration (NMPA) hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie bei Patienten ab 4 Jahren zugelassenMit dieser Zulassung ist AGAMREE die erste und...
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
11 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and...
Santhera erhält von NICE eine positive Empfehlung für AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie
10 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
AGAMREE® wurde von NICE zur Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 4 Jahren in England, Wales und Nordirland empfohlenSanthera wird eng mit dem NHS England, dem NHS Wales und...
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
10 déc. 2024 01h00 HE
|
Santhera Pharmaceuticals Holding AG
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern IrelandSanthera will be working closely with...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
26 oct. 2023 15h19 HE
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
16 oct. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
09 août 2023 16h17 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...